HLA-A and lymphoplasmacytic lymphoma: Patient A underwent allo-HSCT for lymphoplasmacytic lymphoma in partial remission using Fludarabine, BEAM, and Alemtuzumab preparative conditioning, with an HLA-matched unrelated donor with a single HLA-A antigen mismatch (HLA A26 for A32).